Singh R, Barden A, Mori T, Beilin L
Dept of Medicine, University of Western Australia and West Australian Heart Researrch Institute, Perth, Australia.
Diabetologia. 2001 Feb;44(2):129-46. doi: 10.1007/s001250051591.
Advanced glycation end-products are a complex and heterogeneous group of compounds that have been implicated in diabetes related complications. At present it is not known if they are the cause or the consequence of the complications observed. We discuss the chemistry of advanced glycated end-product formation and their patho-biochemistry particularly in relation to the diabetic microvascular complications of retinopathy, neuropathy and nephropathy as well as their role in the accelerated vasculopathy observed in diabetes. The concept of carbonyl stress as a cause for advanced glycated end-product toxicity is mentioned. We discuss alterations in the concentrations of advanced glycated end-products in the body, particularly in relation to changes occurring with age, diabetes and its complications such as nephropathy. Problems relating to current methods of advanced glycated end-product detection and measurement are highlighted including the lack of a universally established method of detection or unit of measurement. Agents used for the treatment of advanced glycated end-product accumulation are reviewed, with an emphasis on the results of the recent phase III trials using aminoguanidine and diabetes related complications.
晚期糖基化终产物是一类复杂且异质的化合物,与糖尿病相关并发症有关。目前尚不清楚它们是所观察到的并发症的原因还是结果。我们讨论晚期糖基化终产物形成的化学过程及其病理生物化学,特别是与视网膜病变、神经病变和肾病等糖尿病微血管并发症的关系,以及它们在糖尿病中观察到的加速血管病变中的作用。文中提到了羰基应激作为晚期糖基化终产物毒性原因的概念。我们讨论了体内晚期糖基化终产物浓度的变化,特别是与年龄、糖尿病及其并发症(如肾病)相关的变化。文中强调了与晚期糖基化终产物检测和测量的当前方法相关的问题,包括缺乏普遍认可的检测方法或测量单位。本文回顾了用于治疗晚期糖基化终产物积累的药物,重点是最近使用氨基胍的III期试验结果和糖尿病相关并发症。